Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Long-term outcome of fludarabine-based reduced intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuria

    ... (PNH) is characterized by intravascular hemolysis , venous- thrombosis , and bone marrow failure . ...

    Research Article last updated 06/02/2014 - 11:39am.

  2. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

    ... (PNH) is characterized by intravascular hemolysis , effectively controlled with eculizumab , a humanized ... during treatment. From 2010 to 2012, clinical data, hemolysis biomarkers, complement assessment and free eculizumab circulating ...

    Research Article last updated 01/20/2015 - 2:28pm.

  3. A retrospective study of paroxysmal nocturnal hemoglobinuria in pediatric and adolescent patients

    ... especially in children, characterized by intravascular hemolysis , thrombotic events, serious infections and bone marrow ...

    Research Article last updated 05/02/2017 - 10:42am.

  4. Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: is eculizumab indicated?

    Journal Title:  Ann Hematol Primary Author:  Bellido M Author(s):  Bellido M,...

    Research Article last updated 07/31/2012 - 12:44pm.

  5. Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion.

    ... acquired disorder characterized by chronic intravascular hemolysis as the primary clinical manifestation and morbidities that ... platelets, resulting in complement-mediated intravascular hemolysis and other complications. Lysis of red blood cells is the most obvious ...

    Research Article last updated 05/14/2013 - 3:28pm.

  6. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria

    ... by florid intravascular, complement-mediated hemolysis , whereas in others, bone marrow failure dominates the clinical picture with modest or even no evidence of hemolysis observed. The clinical heterogeneity is due to the close, though ...

    Research Article last updated 01/26/2017 - 11:03am.

  7. Small-molecule Factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome

    ... on eculizumab have symptomatic extravascular hemolysis , indicating an unmet need for additional therapeutic approaches. ... D inhibitors significantly reduced complement-mediated hemolysis at concentrations as low as 0.01 μΜ. Additionally the compound ...

    Research Article last updated 11/28/2016 - 11:42am.

  8. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan

    ... outcomes included the reduction of intravascular hemolysis , the change in hemoglobin (Hb) level, the withdrawal of ... overall survival. The effect of eculizumab on intravascular hemolysis was demonstrated by a reduction in lactate dehydrogenase ...

    Research Article last updated 11/02/2016 - 10:39am.

  9. Paroxysmal Nocturnal Hemoglobinuria: From Bench to Bed

    ... of this disease arise as a result of complement-mediated hemolysis in unprotected red cells, leukocytes, and platelets as well as ...

    Research Article last updated 11/28/2016 - 11:40am.

  10. Pathogenesis of paroxysmal nocturnal hemoglobinuria

    ... deficient erythrocytes increase in proportion, massive hemolysis occurs due to activated complement attack during infection. As ...

    Research Article last updated 11/02/2016 - 2:52pm.